Nama Insights

Castle Biosciences (CSTL)

Healthcare · Diagnostics Research · NASDAQ

Castle Biosciences (CSTL) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $1.03B and a free-cash-flow yield of 2.9%. Over the most recent reported fiscal year, revenue grew 3.7% and free cash flow per share fell 21.8%. Nama's AI scorecard rates it Hold, 5.2 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Hold · 5.2/10
The sections balance. As of Nov 20, 2026.
Momentum
Lagging · -3.8% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-32.1%
How far the last close sits under the highest price of the past five years.
Market cap$1.03B
Trailing P/E—
Price / book2.1
Price / sales2.7
FCF yield2.9%
Dividend yield—
Gross margin77.1%
Operating margin-7.4%
Net margin-6.1%
Revenue growth (YoY)+3.7%
Revenue growth (3-yr annual)+35.9%
EPS growth (YoY)-237.1%
FCF/share growth (YoY)-21.8%
Beta0.9
ExchangeNASDAQ
SectorHealthcare
IndustryDiagnostics Research

CSTL earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.14). Beat the EPS estimate in 3 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 5, 2026 -$0.13 -$0.35 +62.9% $102.89M
Q2 2026 Jul 30, 2026 -$0.07 -$0.41 +82.9% $103.55M
Q1 2026 May 6, 2026 -$0.49 -$0.49 +0.0% $83.68M
Q4 2025 Feb 26, 2026 -$0.08 -$0.26 +69.2% $87.01M

CSTL analyst price target

Median target $48.50 from 10 analysts, ranging $40.00 – $60.00.

Diagnostics Research peers

TickerCompanyMarket capP/E
TMO Thermo Fisher Scientific $255.19B 27.9
DHR Danaher $160.10B 27.3
WAT Waters $89.71B 31.7
IDXX IDEXX Laboratories $54.33B 46.5
A Agilent Technologies $49.44B 28.9
NTRA Natera $42.04B —
IQV IQVIA $41.29B 19.6
MTD Mettler-Toledo International $33.93B 36.8
Explore live CSTL data on Nama Insights →

CSTL FAQ

Is CSTL a buy?
Nama's AI scorecard currently rates Castle Biosciences Hold (5.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does CSTL report earnings?
Castle Biosciences's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.14.
What is the CSTL price target?
The median analyst price target from 10 analysts is $48.50, with a range of $40.00 – $60.00.
Is CSTL Shariah compliant?
Nama's AAOIFI-style screen reads Castle Biosciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.